
cancer bladder
management
investigation
lab.
cytology
very low
T. markers
S.Q.CC
high grade
80%
low grade
30-50%
non-bilh.
-ve
bilharzial
TCC.
routine
bl. sugar
K.F.T
hepatitis
imaging
instrumental
cystoscopy
biopsy
bimanual e GA
C/P
signs
liver
LN
kidney
palpable
tender
wall thickening
mass
bilharz.
mobile mass
renal mass
meta.
late
impalpable
early
non bilharz.
symptoms
pain
perineal
suprapubic
sciatic
loin
bilharz.
fishy odour
turbid urine
progressive
alarming
exagrated cystitis
no response to med. tft
non-bilhar
renal mass
Asymp.
meta. symp.
exagrated cystitis
irritative symp.
haematuria
advanced
treatment
non-bilharz.
superficial(tis,ta,t1)
low risk
TURT
chemo
no 2nd look or BCG
medium risk
TURT
reTURT
adj.
option
chemo or radio
for 1 y
high risk
TURT
chemo
2nd look
2-4 wks
remove residual
BCG
every 6 wks
then once m 1-3y
CIS
BCG
best
if failed
radical
no TURT
ms-invasion
operable
radical cystectomy
indication
low stage ms inv.
multicentric
high grade
wiz cis
recurrent after TURT
procedure
in male
embloc remove
p 101
in female
ant. pelvic excent.
diversion
incontinant
conduit
U-cut. shunt
continent
skin
anal canal
orthotopic
radioth.
poorer outcome
failed
salvage
genital sparing
bladder sparing
adjuvant
neoadj.
mvac
pharma
surgery
bilh.
non operable
palliation
operable
radical
adj. radio & chemo
inoperable
palliation to pain
evacuate
irrigate
palliation to hematurea
hemostatic
palliation to obstruction
B.neck
no suprapubic
ureters
permenant nephrostomy
staging
TNM
T4
LN or extravesical
T3b
macro. inv.
T3a
T3
micro. inv.
T2b
T2 "ms inv"
to jewett line
T2a
T1
Ta
super. + lamina p.
Tx
superf. epith.
T0
no clinical & histopath.
-ve specimen
strog-jewett-marshall
D
C
LN or other org.
B
transmural
A
muscle inv.
B1 superficial
epithelial
to jewett line
B2 deep
A/E
industerial
tobacco
chemotherapy
ch. irritation
irradiation
phenacetin abuse
bladder Extrophy
epidemiology
age
40-60y
bilharz.
60-80y
non bilharz.
M:F
3:1
pathology
non-bilharz.
Tcc 90%
dysplasia
CIS
superficial
ms. invasive
squamous 7-9%
adenoCA 2%
bilharz.
SQ.C.C75%
TCC.15%
adenoCA8%
fibrillary1-2%
sarcoma
rabdoSA
small cell
adenoCA
urachal
non-urachal
After extrophy